PATH | VRL
Menu

Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture

This article, published in the Journal of Infectious Diseases, describes a novel cell culture-derived influenza vaccine (CCIV) produced in Madin-Darby canine kidney cells. The Phase 3, multicenter study in Poland observed that CCIV was well tolerated and highly immunogenic in adults 18 years of age or older. Cell culture may offer greater flexibility of supply during periods of high demand for both seasonal and pandemic vaccines.

Author: Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al.

Published: 2009

» Visit web page (English)

(Located at www.journals.uchicago.edu)

Citation: Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture. Journal of Infectious Diseases. 2009;200(6):841-846.

Resource types: Peer-reviewed journal

Diseases/vaccines: Influenza

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Eastern Europe